In the study, we utilized four distinct tau transgenic mouse models including an aggressive, early age onset tauopathy (rTg(tauP301L)4510) Mapt0/0; late-onset slowly progressive tauopathy (rTg(tauWT)21221); tau knockout mice (Mapt0/0); mice with a combination of Aβ and NFT pathology (3xTgAD); and age-matched wild type mice. This evidence concerns the gene MAPT and tauopathy.